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Septicemia caused by Neisseria meningitidis is characterized by increasing levels of meningococcal lipopoly-
saccharide (Nm-LPS) and cytokine production in the blood. We have used an in vitro human whole-blood
model of meningococcal septicemia to investigate the potential of CyP, a selective Toll-like receptor 4 (TLR4)–
MD-2 antagonist derived from the cyanobacterium Oscillatoria planktothrix FP1, for reducing LPS-mediated
cytokine production. CyP (>1 g/ml) inhibited the secretion of the proinflammatory cytokines tumor necrosis
factor alpha, interleukin-1 (IL-1), and IL-6 (by >90%) and chemokines IL-8 and monocyte chemoattractant
protein 1 (by 50%) induced by the treatment of blood with pure Nm-LPS, by isolated outer membranes, and
after infection with live meningococci of different serogroups. In vitro studies with human dendritic cells and
TLR4-transfected Jurkat cells demonstrated that CyP competitively inhibited Nm-LPS interactions with TLR4
and subsequent NF-B activation. These data demonstrate that CyP is a potent antagonist of meningococcal
LPS and could be considered a new adjunctive therapy for treating septicemia.
Infections with Neisseria meningitidis (a meningococcus),
characterized by meningitis and potentially fatal septicemia,
continue to be major health problems worldwide (37). The
World Health Organization has estimated that meningococcal
infection accounts for 500,000 new cases each year, with
50,000 deaths (http://www.who.int/csr/resources/publications
/meningitis/whoemcbac983.pdf). The introduction of the con-
jugated serogroup C polysaccharide vaccine into the infant
immunization program has led to a significant decline in sero-
group C infections in developed countries where such vaccines
have been introduced (2), and this strategy is likely to be
extended to the serogroup A, W135, and Y polysaccharides in
developing countries. However, no vaccines exist for prevent-
ing infection by serogroup B meningococci, which are now the
predominant strains in temperate countries.
In individuals lacking humoral immunity to meningococci,
bacterial proliferation in the blood leads to bacteremia and
clinical disease, ranging from mild meningococcemia to men-
ingitis and fulminant septicemia, which is an acute compart-
mentalized intravascular inflammatory response that is char-
acterized by the up-regulation of cytokine and chemokine
production (5). Patients with septicemia rapidly develop life-
threatening symptoms that include persistent circulatory col-
lapse, renal and lung failure, hemorrhagic skin lesions, dissem-
inated intravascular coagulation, and multiple-organ failure
(5). Even with antibiotic treatment, the mortality rate can be as
high as 20 to 50% for patients with fulminant septicemia,
whereas that for patients with meningitis but without septicemia
is 5% (7).
It is generally accepted that the meningococcal lipopolysac-
charide (designated Nm-LPS), which resides in the outer mem-
brane (OM) of the bacterium, is largely responsible for induc-
ing intravascular inflammation (7). Indeed, the progression of
fulminant septicemia closely correlates with increasing levels
of circulating Nm-LPS and the consequent production of cy-
tokines, notably interleukin-6 (IL-6), tumor necrosis factor al-
pha (TNF-), IL-1, and IL-8 (5, 9, 39). LPS-stimulated cyto-
kine production by myeloid cells is believed to depend on the
association of LPS and the serum LPS-binding protein, which
then forms a multimer with CD14 (41), a glycophosphatidyl-
inositol-linked cell surface glycoprotein on the myeloid cell
surface (18). The association of this complex with an adjacent
Toll-like receptor 4 (TLR4) molecule (3) and an accessory
protein MD-2 molecule (35) (designated TLR4–MD-2) trans-
duces the LPS signal via MyD88 (30) to eventually activate
nuclear factor kappa B (NF-B) and trigger cytokine produc-
tion (31). The activation of monocytes by Nm-LPS has been
shown to be dependent on CD14 and TLR4–MD-2 (44).
Recently, an LPS-related molecule derived from the cya-
nobacterium Oscillatoria planktothrix FP1 and termed CyP was
reported to act as a selective TLR4–MD-2 receptor antagonist
(28). The Cyanobacteria form a very large taxa, and the chem-
ical analysis of cyanobacterial LPS has shown that although
these molecules are basically similar to LPS from gram-nega-
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tive bacteria, there are differences between the two in chemical
and biological properties (22). Neisseria meningitidis gram-neg-
ative LPS consists of symmetrical hexa-acyl lipid A, a core struc-
ture containing two 2-keto-deoxy-octulosonic acids (KDO) and
two heptoses (L-glycero-D-manno-heptopyranoside) with short
polysaccharide side chains attached. However, unlike most en-
teric gram-negative LPS, there are no multiple repeating units of
O antigens in meningococcal LPS (21). LPS molecules derived
from cyanobacteria, including various Oscillatoria spp., contain
glucose, xylose, mannose, and rhamnose, but unlike gram-nega-
tive LPS, the presence of galactose and glucosamine is variable
and both KDO and heptose either are present in low concentra-
tions (0.15 to 2% of LPS) or are absent (22, 28). Cyanobacterial
LPS molecules also contain relatively large quantities of oleic,
palmitoleic, linoleic, and linolenic acids, which typically are absent
from gram-negative LPS molecules. In addition, unlike lipid A
from gram-negative LPS, including the Nm-LPS, lipid A from
cyanobacteria does not contain phosphorus (22).
The cyanobacterial LPS-related molecule CyP acted as a
competitive inhibitor of Escherichia coli LPS binding to the
receptor complex on human dendritic cells (DC) (28). In ad-
dition, CyP was nontoxic in mice in vivo, and it was nontoxic in
both human and mouse cells in vitro and did not itself stimu-
late DC responses (28). Significantly, CyP suppressed gene
transcription and cytokine production in DC treated with E.
coli LPS and also protected mice from endotoxic shock caused
by Salmonella enterica serovar Abortusequi LPS (28). In the
current study, we used an in vitro human whole-blood model of
Neisseria meningitidis septicemia to evaluate the potential of
CyP as an antagonist able to reduce the intravascular inflam-
matory response.
MATERIALS AND METHODS
Bacteria and growth conditions. Neisseria meningitidis strain MC58 (B:15:
P1.7,16b) was isolated from an outbreak of meningococcal infections that oc-
curred in Stroud, Gloucestershire, United Kingdom, in the mid-1980s (29).
Neisseria meningitidis serogroup C strain MenC11 (15) was obtained from the
Meningococcal Reference Unit of the Manchester Health Protection Agency,
and serogroups A (strain designation MC12), X (MC27), Y (MC31), W135
(MC39), and Z (MC34) were obtained from the Scottish Meningococcal Refer-
ence Unit (Glasgow, Scotland).
All bacteria were grown at 37°C in an atmosphere containing 5% (vol/vol) CO2
on supplemented proteose-peptone agar (43) and suspended in phosphate-buff-
ered saline (PBS) for infection experiments.
Preparation of OM and Nm-LPS. Outer membranes (OM) were prepared by
the extraction of wild-type MC58 whole cells with lithium acetate (40), and
Nm-LPS was purified from MC58 by extraction with hot phenol, as described
previously (12, 23). LPS from Escherichia coli serotype 0111:B4 was purchased
from Sigma (Poole, Dorset, United Kingdom). The quantitation of both Nm-LPS
and E. coli LPS was based on dry weight. OM and LPS preparations were
suspended in sterile, endotoxin-free PBS (100 l) prior to addition to whole
blood.
CyP. CyP was purified from the freshwater cyanobacterium Oscillatoria plank-
tothrix FP1 by a phenol-guanidinium thiocyanate-based method as described
previously (28). The silver staining of the purified cyanobacterial extract sepa-
rated by deoxycholate-polyacrylamide gel electrophoresis mainly showed the
presence of an LPS-like glycolipid (28), and contamination was minimal and
similar to that observed for commercially available gram-negative LPS products.
Protein contamination was 3% (wt/wt), and mean nucleic acid contamination
was 30% (and consisted mainly of degraded RNA). The level of KDO was low
(0.15%, wt/wt), and endotoxin activity, as quantified by the Limulus amoebocyte
lysate assay, was 4 endotoxin units (EU)/mg; that for E. coli LPS was 15,000
EU/mg (28). The concentration of CyP was estimated using the Pro-Q-emerald
300 LPS gel stain kit (Invitrogen), and each band was quantitated using a
charge-coupled display camera. In addition, the specific activity of CyP was
determined by the inhibition of TNF- production in culture supernatants of
human THP1 cells stimulated with E. coli LPS and are expressed as the mean
inhibition per microgram of CyP.
Several biological assays were carried out to confirm the purity of CyP. The
absence of stimulatory activity by CyP preparation alone was confirmed by the
absence of TNF- production in THP1 cells. In addition, when added to gran-
ulocyte-macrophage colony-stimulating factor (GM-CSF)-cultured DC derived
from the bone marrow of wild-type CH3/HeN, BALB/C, or C57BL/6 mice, CyP
(20 g/ml) did not induce TNF- or IL-6 secretion. Significantly, in experiments
with DC derived from the bone marrow of TLR4-defective C3H/HeJ mice, CyP
(20 g/ml) also did not induce TNF- or IL-6 secretion. In addition, no NF-B
activity was observed in human Jurkat cells transfected with human TLR2 and
human TLR9 after treatment with CyP (data not shown). Moreover, CyP has
been reported to bind to MD-2, LPS-binding protein, and polymyxin B (28), thus
demonstrating strong similarities to gram-negative bacterial LPS. CyP was dis-
solved in sterile, endotoxin-free PBS prior to addition to whole blood.
Human whole-blood model. The whole-blood model was carried out according
to the procedure described by Ison (20). Whole human venous blood was taken
from a healthy volunteer with informed consent, collected into sterile Vacutainer
tubes containing sodium heparin anticoagulant (Becton Dickinson Systems, New
Jersey), and processed within 1 h. Whole blood (1 ml) was dispensed into sterile
24-well tissue culture plates (Greiner bio-one; Germany), and triplicate wells
were treated with various concentrations of live bacteria, isolated OM, or LPS
from meningococci (Nm-LPS) or E. coli cells (Ec-LPS) in the presence of various
concentrations of CyP. In addition, control wells consisted of blood alone and
blood with CyP only. The plates were incubated at 37°C, initially on a rocking
table (20 rpm) for the first 3 h and then without rocking for the remainder of the
experiment(s). Samples were taken at 6 and 24 h and centrifuged (13,000  g for
5 min), and the plasma layer was removed and stored at 	20°C for analysis.
Measurement of cytokine production in human plasma. The levels of the
proinflammatory (IL-1, IL-1, IL-6, and TNF-), chemoattractant (monocyte
chemoattractant protein 1 [MCP-1], IL-8, and regulated upon activation, normal
T cell expressed and secreted [RANTES]), anti-inflammatory (IL-10), and
growth factor-related (GM-CSF) cytokine proteins were quantified by sandwich
immunoassay, as described previously (12). A two-sample t test was used to
compare the mean levels of cytokine secretion after particular treatments, with
P  0.05 being significant.
Isolation and stimulation of human mo-DC. Buffy coats were obtained from
the Swiss Blood Center, Basel, Switzerland, and ethical permission for the use of
human primary cells was obtained from the Federal Office of Public Health of
Switzerland. Monocytes were purified from peripheral blood mononuclear cells
by positive sorting using anti-CD14-conjugated magnetic microbeads (Miltenyi).
Monocyte-derived DC (mo-DC) were generated as described previously by cul-
turing monocytes in RPMI medium supplemented with 10% (vol/vol) fetal bo-
vine serum, GM-CSF (Gentaur), and IL-4 (33). mo-DC (0.5 106 cells/ml) were
stimulated with Nm-LPS or Ec-LPS (100 ng/ml) in the absence or presence of
CyP (2.5 to 20 g/ml). The production of human TNF- and IL-6 cytokines was
measured in mo-DC supernatant fluids after stimulation for 20 h, using DuoSet
enzyme-linked immunosorbent assay development kits (R&D Systems). Cyto-
kine data are from measurements with standard deviations below 5%.
TLR4 transfection assay. Human Jurkat cells (1  107; expressing human
MD-2) were transfected as described previously (28) by electroporation (250 V,
975 F; Gene Pulser II; Bio-Rad) with 1.5 g of expression vector encoding
human TLR4 together with 1 g of 3 NF-B luciferase reporter vector (kindly
provided by G. Natoli; IFOM, Milan, Italy). After 24 h, the cells were washed,
resuspended in 12 ml of fresh medium, and plated onto 12-well plates with 0.8 ml
of cells for each stimulatory condition (100 ng/ml of Nm-LPS or Ec-LPS, in the
absence or presence of 5 to 20 g/ml of CyP). After 8 h of stimulation, the cells
were harvested and lysed, and reporter gene activity was measured using the
luciferase assay system (Promega) and Veritas luminometer (Turner BioSys-
tems) according to the manufacturers’ instructions. Jurkat cells transfected with
empty vector together with 3 NF-B luciferase reporter vector were used as a
mock control. Luciferase activity in the presence of CyP is shown as a mean
percentage of the activity observed from cells stimulated with LPS alone (100%),
with error bars denoting the standard deviations.
RESULTS
Effect of cyanobacterial LPS antagonist CyP on cytokine
production in human whole blood treated with Nm-LPS. Our
first experiments were aimed at investigating the effects of CyP
on cytokine production in human whole blood treated with
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various doses (1 fg/ml to 1,000 ng/ml) of pure LPS from Neis-
seria meningitidis (Nm-LPS) and Escherichia coli (Ec-LPS).
Initially, a concentration of 20 g/ml of CyP was used in these
experiments according to the study of Macagno and col-
leagues, who demonstrated that this concentration effectively
suppressed Ec-LPS-induced cytokine production by human
mo-DC in all experimental conditions tested (28).
CyP was added to whole blood at the same time (t 
 0 h) as
each LPS preparation, and cytokine production was measured
after 6 h. Doses of Nm-LPS alone of between 0.01 and 1,000
ng/ml induced proinflammatory cytokines IL-1, IL-6, and
TNF- and the chemokines IL-8 and MCP-1 in whole blood
(Fig. 1A), whereas doses of 0.01 ng/ml had no significant
effect. CyP inhibited the secretion of IL-1, IL-6, and TNF-,
which was induced by doses of 0.1 to 1 ng/ml Nm-LPS, by
95% (P  0.05) and by between 50 and 85% (P  0.05) for
cytokines induced by 10 ng/ml Nm-LPS (Fig. 1A). No cytokine
inhibition (P  0.05) was observed with the highest doses of
Nm-LPS tested (100 to 1,000 ng/ml).
By contrast, the secretion of the chemokines IL-8 and
MCP-1 was not inhibited by CyP but was indeed increased
(Fig. 1A). Significantly, CyP (20 g/ml) alone induced these
chemokines, and an additive effect was observed in the pres-
ence of high doses of Nm-LPS. CyP and Nm-LPS (10 to 100
ng/ml) together induced approximately three- to fourfold in-
creases in IL-8 and MCP-1 (P 0.05) levels compared to those
of secretions induced by Nm-LPS alone (Fig. 1A).
We next investigated whether the effects of CyP on cytokine
production in whole blood treated with Nm-LPS were a gen-
eral feature of its antagonist properties toward gram-negative
LPS. Therefore, similar experiments were carried out with
Ec-LPS. As observed with Nm-LPS, CyP inhibited the secre-
tion of IL-1, IL-6, and TNF- induced by Ec-LPS, with a
reduction of between 70 and 98% (P  0.05) in cytokine levels
induced by doses of 1 to 100 ng/ml (Fig. 1B). In addition, a
synergistic effect between CyP and the highest dose of Ec-LPS
(100 ng/ml) resulted in increased IL-8 induction compared to
that of induction by CyP alone, but a similar effect was not
observed for MCP-1 (Fig. 1B).
During the course of these (and subsequent) experiments,
there was no hemolysis or other visible signs of toxicity, such as
cell clumping or floating cells in control wells containing hu-
man whole blood treated with CyP (20 g/ml) alone. This lack
of toxicity is consistent with the previous study from Macagno
and colleagues (28), who reported that CyP also was nontoxic
in vivo in mice and in vitro in human and mouse cell lines.
CyP inhibits Nm-LPS-induced proinflammatory cytokine
production by human mo-DC and TLR4-mediated NF-B ac-
tivity. A previous study with human mo-DC demonstrated that
CyP inhibited LPS from E. coli by interacting with the TLR4–
MD-2 extracellular domain (28), and we investigated whether
this mechanism was involved in the CyP inhibition of Nm-LPS
activity as well. This was studied with two well-characterized
systems, namely, the culture of mo-DC with the measurement
of TNF- and IL-6 secretion as biological markers of activa-
tion, and the measurement of luciferase activity as a marker of
NF-B activation in human MD-2-positive Jurkat cells trans-
fected to ectopically express human TLR4.
Treatment with Nm-LPS and Ec-LPS induced similar levels
of both TNF- and IL-6 secretion by mo-DC (Fig. 2A). The
optimal inhibition of TNF- and IL-6 release induced by Nm-
LPS required 10 to 20 g/ml of CyP, concentrations that were
four- to eightfold higher (P  0.05) than the dose of CyP (2.5
g/ml) required for inhibiting Ec-LPS-induced secretion. In
experiments with Jurkat cells, both LPS molecules (100 ng/ml)
stimulated NF-B activity only in cells transfected with TLR4,
and this activity was significantly inhibited (70 to 80%; P 
0.05) by CyP at all doses tested (Fig. 2B). When both LPS
molecules were tested at a higher concentration of 400 ng/ml,
40 to 70% inhibition was observed depending on the dose of
CyP (data not shown).
Effect of CyP on cytokine production in human whole blood
treated with meningococcal OM. A characteristic feature of
meningococcal infection is the shedding of OM vesicles, or
FIG. 1. Effect of CyP on proinflammatory cytokine and chemo-
kine production in whole human blood treated with various doses of
Nm-LPS or Ec-LPS. Whole blood (1 ml) either was left untreated or
was treated with Nm-LPS (A) or Ec-LPS (B) in the presence or
absence of CyP (20 g/ml) or CyP alone, and cytokine production
was measured after 6 h. The columns represent mean cytokine
secretion for three independent wells, and the error bars represent
the standard deviations. Data are shown from representative exper-
iments (n 
 6). , P  0.05.
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blebs, and these structures are believed to constitute the main
mechanism by which LPS is disseminated rapidly during bac-
teremia (32, 36). In the current study, human whole blood was
incubated with various doses of OM (0.01 to 100 ng protein/
ml) in the presence or absence of CyP (20 g/ml), and
cytokine production was quantified after 6 h. CyP signifi-
cantly inhibited the secretion of IL-1, IL-6, and TNF-
induced by doses of 10 to 100 ng/ml OM by between 70 and
99% (P  0.05) (Fig. 3). By contrast, a synergistic effect
between CyP and the highest dose of OM (100 ng/ml) re-
sulted in increased IL-8 induction compared that of CyP
alone, but a similar effect was not observed for MCP-1 (Fig.
3). Thus, the pattern of cytokine production induced by OM
was similar to that observed with pure LPS molecules and
was inhibited by CyP. Similarly, no inhibitory effect was
observed on chemokine production induced by OM.
CyP inhibits proinflammatory cytokine production in hu-
man whole blood infected with live Neisseria meningitidis. We
next investigated whether CyP could inhibit cytokine secretion
induced by meningococcal infection. Human whole blood was
infected with various doses of live serogroup B Neisseria men-
ingitidis strain MC58 (102 to 108 CFU/ml), a range that covers
the concentrations observed during bacteremia (5, 7), in the
presence or absence of CyP (20 g/ml), and cytokine secretion
was quantified after 6 h. Infection with doses of bacteria of
104 CFU/ml resulted in the significant production of proin-
flammatory cytokines (Fig. 4). CyP strongly inhibited (by 80 to
93%; P  0.05) the secretion of IL-1, IL-6, and TNF- in-
duced by 104 meningococci. At the higher dose of 106 bacteria,
the inhibitory effect of CyP was less pronounced, with a reduc-
tion (P  0.05) of IL-1 and IL-6 levels by approximately 30
and 20%, respectively, but with no effect (P  0.05) on TNF-
secretion (Fig. 4). CyP did not inhibit proinflammatory cyto-
kine secretion induced by 108 meningococci (P  0.05), and as
observed with pure LPS and OM, CyP also did not inhibit IL-8
or MCP-1 secretion. At certain bacterial doses, it resulted in
additive levels of chemokine production (Fig. 4).
We next sought to determine if CyP also showed inhibitory
activity toward other meningococcal serogroups. Therefore,
human whole blood was infected with 104 CFU/ml of a selec-
tion of different serogroups in the presence or absence of CyP
(20 g/ml), and cytokine production was quantified at 6 h.
Serogroup A, B, C, W135, X, and Z meningococci all induced
proinflammatory cytokines and chemokines. CyP significantly
inhibited (P  0.05) the secretion of IL-1, IL-6, and TNF-
induced by all serogroup bacteria, with mean levels of inhibi-
FIG. 2. Effect of CyP on LPS-induced proinflammatory cytokine
production by human DC and TLR4-mediated NF-B activity.
(A) Human mo-DC were treated with Nm-LPS or Ec-LPS and various
doses of CyP (0 to 20 g/ml), and TNF- and IL-6 cytokine secretion
was measured. Data are representative of two independent experi-
ments. (B) Human Jurkat cells (expressing human MD-2), transfected
to express human TLR4, were treated with Nm-LPS or Ec-LPS and
various doses of CyP (0 to 20 g/ml), and luciferase activity measured
as a marker of NF-B activation. The columns represent the mean
luciferase activity from three independent wells, and the error bars
represent the standard deviations. Data are shown for a representative
experiment (n 
 2).
FIG. 3. Effect of CyP on proinflammatory cytokine and chemokine
production in whole human blood treated with various doses of
meningococcal OM. Whole blood (1 ml) either was left untreated or
was treated with OM in the presence or absence of CyP (20 g/ml) or
with CyP alone, and cytokine production was measured after 6 h. The
columns represent mean cytokine secretion for three independent
wells, and the error bars represent the standard deviations. , P 0.05.
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tion ranging from 70% for IL-6 to97% for IL-1 and TNF-
(data not shown). As observed with serogroup B meningococ-
cal infection at the higher dose of 106 CFU, the inhibitory
effect of CyP also was generally less pronounced against infec-
tion with the other serogroup bacteria. However, CyP did show
a capacity to inhibit cytokine secretion induced by some sero-
groups more effectively than others. For example, whereas CyP
did not inhibit the secretion of TNF- induced by serogroups
B and C (P  0.05) and showed only low levels of inhibition
(10%) toward W135 and X (P  0.05), it inhibited cytokine
secretion induced by serogroups A and Z by approximately
56% (P 0.05; data not shown). In addition, CyP inhibited the
serogroup C stimulation of IL-1 secretion by approximately
8% (P 0.05) but showed higher activity against serogroups A,
X, W135, and Z, reducing cytokine secretion by between 35
and 50% (P  0.05). By contrast, CyP inhibited IL-6 secretion
induced by all the serogroups similarly, with a reduction of
between 10 and 20% (P  0.05) (data not shown).
Effect of various doses of CyP on cytokine production in
human whole blood infected with live Neisseria meningitidis or
treated with pure Nm-LPS. Thus far, our data have demon-
strated that a dose of 20 g/ml CyP (28) inhibited proinflam-
matory cytokine (IL-1, IL-6, and TNF-) secretion in human
whole blood treated with live meningococci, Nm-LPS, and
native OM. However, CyP at this concentration stimulated
chemokine production. Therefore, we investigated whether us-
ing lower concentrations of CyP could reduce chemokine se-
cretion but still effectively suppress proinflammatory cytokine
production induced by live bacteria and Nm-LPS.
Human whole blood was treated with 104 CFU/ml of live
Neisseria meningitidis MC58 and various doses of CyP from
0.01 to 20 g/ml, and cytokine production was quantified at 6 h
(Fig. 5). The significant inhibition (P  0.05) of proinflamma-
tory cytokines was effected by CyP doses as low as 0.1 g/ml. At
this dose, the levels of IL-1, IL-6, and TNF- were reduced by
approximately 65 to 80% (Fig. 5). Increasing the dose of CyP
to 1 g/ml reduced IL-1 and IL-6 secretion by 90%, and
in the case of TNF-, optimal inhibition (95%) was observed
with doses of 1 to 5 g/ml CyP. Treatment of blood with CyP
alone resulted in a dose-dependent increase in the chemokines
IL-8 and MCP-1, but minimal induction was observed with the
lowest doses of CyP tested (0.01 to 1 g/ml). Moreover, doses
of 0.1 to 1 g/ml CyP resulted in the inhibition of IL-8 and
MCP-1 secretion by approximately 50% (P 0.05) rather than
the stimulation seen at higher concentrations (Fig. 5).
Similar results were observed with Nm-LPS. When whole
blood was treated with 1 ng/ml Nm-LPS, the minimal dose of
CyP required to inhibit IL-1, IL-6, and TNF- secretion by
95% (P  0.05) was 1 g/ml CyP. At a higher dose (10 ng/ml
Nm-LPS), doses of 5 g/ml CyP were required for the sig-
nificant inhibition (P 0.05) of cytokine secretion. In addition,
a dose of 1 g/ml CyP inhibited IL-8 and MCP-1 secretion
induced by 1 to 10 ng/ml Nm-LPS by approximately 50% (P 
0.05) (data not shown).
Finally, during the course of all these experiments, neither
IL-1, GM-CSF, nor the anti-inflammatory cytokine IL-10
were induced by Nm-LPS, Ec-LPS, isolated OM, live bacteria,
and/or CyP. In addition, RANTES was the only molecule de-
tected in normal, untreated whole blood, but its levels re-
mained unchanged following any of the treatments with or
without CyP (data not shown).
DISCUSSION
For patients with meningococcal septicemia, there is a direct
correlation between increasing levels of Nm-LPS in the blood
and the production of high concentrations of cytokines, includ-
ing IL-1, TNF-, IL-6, and IL-8 (5, 7). Although antibiotic
therapy is the primary treatment for meningococcal infection
and the plasma levels of both LPS and cytokines have been
reported to decline immediately following administration (8),
adjunctive therapies that neutralize LPS likely would improve
clinical outcomes. However, the results from the clinical trials
of some candidate therapies have been disappointing. Neither
human serum antibodies to the rough E. coli J5 mutant that
expresses the LPS core structure nor HA-1A, a human/mouse
chimeric monoclonal antibody directed against lipid A, re-
duced the mortality rate in patients with meningococcal septi-
cemia (13, 16). In addition, although treatment with the re-
combinant 21-kDa N-terminal fragment of bactericidal/
permeability-increasing protein did reduce some complications
of meningococcal sepsis, the trial was unable to detect differ-
ences in mortality (25). The current study was undertaken to
investigate the use of CyP, a cyanobacterial LPS antagonist, as
a potential therapy for down-regulating cytokine production in
a human whole-blood model after treatment with Nm-LPS and
OM and after infection with live meningococci.
FIG. 4. Effect of CyP on proinflammatory cytokine and chemokine
production in whole human blood infected with serogroup B Neisseria
meningitidis strain MC58. Whole blood (1 ml) either was left untreated
or was infected with various doses of meningococci in the presence or
absence of CyP (20 g/ml)or CyP alone, and cytokine production was
measured after 6 h. The columns represent mean cytokine secretion
for three independent wells, and the error bars represent the standard
deviations. Data are shown for a representative experiment (n 
 2).
, P  0.05.
3160 JEMMETT ET AL. INFECT. IMMUN.
 o
n
 N
ovem
ber 14, 2016 by Universita Dell Insubria
http://iai.asm
.org/
D
ow
nloaded from
 
In the current study, CyP was a potent antagonist for Nm-
LPS, significantly inhibiting the secretion of IL-1, TNF-, and
IL-6. Moreover, the fact that CyP similarly inhibited cytokine
secretion induced by Ec-LPS suggests that CyP acts through a
common mechanism as an antagonist of the activity of gram-
negative LPS. This was demonstrated by the findings that CyP
efficiently inhibited cytokine production from human mo-DC
treated with both Nm-LPS and Ec-LPS and, moreover, that
both LPS molecules stimulated NF-B activity in Jurkat cells
expressing human MD-2 transfected with TLR4. Our data are
consistent with the study of Macagno et al., which reported
that CyP acted as a specific TLR4–MD-2 antagonist, directly
binding to MD-2 to competitively inhibit LPS binding and the
downstream activation of NF-B (28).
In the current study, CyP also was antagonistic to meningo-
coccal LPS in the form that it is naturally presented during
infection, i.e., as a major component of OM blebs and on intact
bacteria. This is particularly significant, since increasing levels
of Nm-LPS in the blood reflect bacterial growth and the re-
lease of OM blebs, events that closely correlate with the de-
velopment of septic shock, multiple-organ failure, and death
(6). CyP potently inhibited cytokine production in whole blood
that had been treated with up to 10 ng/ml Nm-LPS, 100 ng/ml
OM, and 104 CFU/ml of live bacteria. Clinical studies have
reported that levels of purified or OM-bound LPS of 0.7
ng/ml were associated with bacteremia in all patients, with a
range from 0.6 ng/ml in individuals with mild systemic menin-
gococcal disease (8) to 2 to 3 ng/ml for systemic meningococcal
disease patients with persistent septic shock (6, 7, 14, 38).
Thus, CyP could inhibit cytokine production in vitro induced
by levels of bioactive LPS that are found in patients with
meningococcal septicemia. Moreover, cytokine inhibition was
independent of the meningococcal serogroup, demonstrating
broad applicability, and CyP itself had no effect on meningo-
coccal viability or growth.
In contrast to its effects on proinflammatory cytokine pro-
duction, CyP alone, at the highest concentration tested (20
g/ml), induced the secretion of chemokines IL-8 and
MCP-1 in whole blood. Although the CyP preparation con-
sists mainly of an LPS-like glycolipid, which most likely is
responsible for the antagonistic effects (28), it is possible
that minor contaminants are responsible for stimulating
chemokine expression. However, several other possibilities
cannot be excluded. In the complex heterogeneous cell en-
vironment of whole human blood, it is possible that CyP
itself induces chemokine secretion by stimulating cells such
as neutrophils and monocytes in a TLR4-independent man-
ner and/or by up-regulating chemokine receptor expression.
FIG. 5. Effect of various concentrations of CyP on proinflammatory cytokine and chemokine production in whole human blood treated with
live meningococci. Whole blood (1 ml) either was left untreated or was infected with approximately 104 CFU of strain MC58 and various doses
of CyP (0.01 to 20 g/ml) or CyP alone, and cytokine production was measured after 6 h. The columns represent mean cytokine secretion for three
independent wells, and the error bars represent the standard deviations. Data are shown for a representative experiment (n 
 2). , P  0.05.
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Furthermore, despite the fact that these chemokines were
not transcriptionally induced in human DC by CyP (28), it is
possible that in different cells the threshold levels for the
induction of chemokines are lower than those for proinflam-
matory cytokines; thus, when CyP competitively binds to the
TLR4–MD-2 receptor complex and inhibits Nm-LPS inter-
action, low levels of CyP activation and signaling may occur
that are sufficient to induce some expression of IL-8 and
MCP-1 but not of IL-1, IL-6, and TNF-. The current
study also demonstrated that an additive effect on IL-8 and
MCP-1 secretion sometimes was observed with the highest
concentrations of CyP (20 g/ml) and Nm-LPS tested. In
this case, it is possible that Nm-LPS with CyP and/or minor
contaminants are acting synergistically on TLR4–MD-2
and/or other, as-yet uncharacterized receptors on the sur-
faces of blood cells. Although these exact mechanisms re-
main unknown, by reducing the concentration of CyP to 1
g/ml, the efficient inhibition of proinflammatory cytokine
production still was observed; however, the significant,
though not total, down-regulation of chemokine secretion
induced by Nm-LPS and live bacteria also occurred. Nota-
bly, cytokine and chemokine inhibition still was observed
after 24 h (data not shown). Therefore, it is possible to
modulate the concentration of a single dose of the CyP
preparation in order to maintain an immunosuppressive ef-
fect on cytokine production while permitting some chemo-
kine production. This may be important in vivo as a mech-
anism for controlling the recruitment of immune effector
cells necessary for pathogen removal without increasing the
damage to host cells due to the release of microbicidal
agents.
The efficacy of CyP in the human whole-blood model of
septicemia was dependent on the time of administration. In
the current study, CyP was effective when added to blood
within 1 h of stimulation with meningococci or meningococ-
cal components but not at later times (data not shown). This
contrasts with the study of Macagno and colleagues, which
reported that Ec-LPS-induced cytokine production by puri-
fied mo-DC could be inhibited by CyP added up to 6 h after
endotoxin stimulation (28). It is likely that both the cellular
heterogeneity of whole human blood and the rapid activa-
tion of different myeloid cells by meningococcal compo-
nents, compared to the activation of a monoculture of
mo-DC in vitro, explains in part the differences in biological
effects observed.
Many studies have described different lipid A analogues
and chemically modified LPS derivatives (10, 11, 19, 27, 34)
as well as LPS-neutralizing molecules (1, 4, 17) as potential
inhibitors of inflammatory responses induced by Ec-LPS. To
date, only LPS-like molecules isolated from the bacteria
Rhodobacter capsulatus, Helicobacter pylori, Porphyromonas
gingivalis, Capnocytophaga ochracea, and Oscillatoria planktothrix
FP1 have been reported to act as LPS receptor antagonists
(24, 26, 28, 42). To our knowledge, the current study is the
first report demonstrating that CyP, an LPS-like molecule
derived from a cyanobacterium, is a potent antagonist of
Nm-LPS, inhibiting cytokine production in an in vitro model
of septicemia. Therefore, CyP represents a potentially new
adjunctive therapy for the treatment of meningococcal sep-
ticemia and other endotoxin-mediated inflammatory re-
sponses.
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